Cai B, Roy D K, Sciacca R, Michler R E, Cannon P J
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Int J Cardiol. 1995 Jul;50(3):243-51. doi: 10.1016/0167-5273(95)02384-9.
Recent studies have indicated a role for nitric oxide (NO) in alloimmune responses and in allograft rejection. iNOS mRNA, protein and enzyme activity are induced in myocardium during cardiac allograft rejection. NO produced by iNOS is negatively inotropic and has the potential to be cytotoxic to cardiac myocytes. To investigate whether immunosuppressive agents would alter the expression of iNOS during cardiac allograft rejection, hearts from Wistar-Furth rats were transplanted into the abdomen of Lewis recipients. At day 5 allografts from treated and untreated animals were removed for pathological and biochemical examination. At day 5 the untreated allografts exhibited histological evidence of marked rejection (edema, infiltration with macrophages and lymphocytes, necrosis of cardiac muscle fibers). Abundant iNOS mRNA was apparent in Northern blots and iNOS enzyme activity was increased in ventricular homogenates and in cardiac myocytes purified from the untreated rejecting allografts. Incubation of isolated purified cardiac myocytes from normal rats for 24 h with cytokines known to be present during allograft rejection (IL-1 beta, TNF-alpha and IFN-gamma) was also associated with increased iNOS mRNA and enzyme activity. When Wistar-Furth to Lewis allografts were treated from time of transplantation with FK 506, cyclosporine A, dexamethasone or a combination of all three drugs, histological evidence of rejection and the levels of iNOS mRNA and enzyme activity in ventricular homogenates were reduced significantly below those observed in the untreated allografts. The data in a rat model indicate that immunosuppressive drugs reduce myocardial iNOS mRNA and enzyme activity in rejecting cardiac allografts. The results are consistent with the hypothesis that the alloimmune response and cytokine release are involved in the expression of iNOS during cardiac transplantation rejection.
最近的研究表明,一氧化氮(NO)在同种免疫反应和同种异体移植排斥中发挥作用。在心脏同种异体移植排斥反应期间,心肌中诱导型一氧化氮合酶(iNOS)的信使核糖核酸(mRNA)、蛋白质和酶活性增加。iNOS产生的NO具有负性肌力作用,并且有可能对心肌细胞产生细胞毒性。为了研究免疫抑制剂是否会改变心脏同种异体移植排斥反应期间iNOS的表达,将Wistar-Furth大鼠的心脏移植到Lewis受体的腹部。在第5天,将来自治疗组和未治疗组动物的同种异体移植物取出进行病理和生化检查。在第5天,未治疗的同种异体移植物表现出明显排斥的组织学证据(水肿、巨噬细胞和淋巴细胞浸润、心肌纤维坏死)。在Northern印迹中,iNOS的mRNA大量出现,在未治疗的排斥性同种异体移植物的心室匀浆和纯化的心肌细胞中,iNOS酶活性增加。用已知在同种异体移植排斥反应期间存在的细胞因子(白细胞介素-1β、肿瘤坏死因子-α和干扰素-γ)对正常大鼠分离纯化的心肌细胞进行24小时孵育,也与iNOS的mRNA和酶活性增加有关。当Wistar-Furth大鼠到Lewis大鼠的同种异体移植物从移植时开始用FK 506、环孢素A、地塞米松或这三种药物的组合进行治疗时,排斥的组织学证据以及心室匀浆中iNOS的mRNA和酶活性水平显著低于未治疗的同种异体移植物。大鼠模型中的数据表明,免疫抑制药物可降低排斥性心脏同种异体移植物中心肌iNOS的mRNA和酶活性。这些结果与以下假设一致,即同种免疫反应和细胞因子释放参与心脏移植排斥反应期间iNOS的表达。